Compass Therapeutics (NASDAQ:CMPX) Upgraded by Raymond James Financial to Outperform Rating

Raymond James Financial upgraded shares of Compass Therapeutics (NASDAQ:CMPX) to an outperform rating in a research report released on Tuesday, MarketBeat Ratings reports. The firm currently has $9.00 target price on the stock.

Several other brokerages also recently weighed in on CMPX. D. Boral Capital restated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. HC Wainwright reiterated a “buy” rating and set a $24.00 price objective on shares of Compass Therapeutics in a report on Monday, April 21st. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Buy” and a consensus price target of $12.67.

Compass Therapeutics Price Performance

CMPX opened at $2.78 on Tuesday. The firm has a market capitalization of $383.73 million, a PE ratio of -6.77 and a beta of 1.48. The business’s 50-day moving average is $2.21 and its two-hundred day moving average is $2.28. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). As a group, sell-side analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling at Compass Therapeutics

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider owned 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter valued at $35,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Compass Therapeutics by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Compass Therapeutics by 25.2% during the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock worth $404,000 after purchasing an additional 56,000 shares during the last quarter. ProShare Advisors LLC lifted its position in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after purchasing an additional 9,451 shares during the period. Finally, Barclays PLC lifted its position in Compass Therapeutics by 13.2% during the fourth quarter. Barclays PLC now owns 192,766 shares of the company’s stock valued at $279,000 after purchasing an additional 22,521 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.